Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine – from HIV-1 infection to COVID-19

References

• Weniger H. Review of side effects and toxicity of chloroquine. Bull World Health. 1979;79:906.
   Google Scholar
• Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–73.
   PubMed Web of Science ®Google Scholar
• Wang LF, Lin YS, Huang NC, et al. Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery. J Interferon Cytokine Res. 2015;35(3):143–156.
   PubMed Web of Science ®Google Scholar
• Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents. 2007;30(4):297–308.
   PubMed Web of Science ®Google Scholar
• Chiang G, Sassaroli M, Louie M, et al. Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine. Clin Ther. 1996;18(6):1080–1092.
   PubMed Web of Science ®Google Scholar
• González-Hernández I, Aguirre-Cruz L, Sotelo J, et al. Distribution of hydroxychloroquine in lymphoid tissue in a rabbit model for HIV infection. Antimicrob Agents Chemother. 2014;58(1):584–586.
   PubMed Web of Science ®Google Scholar
• Routy JP, Angel JB, Patel M, et al. Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy. HIV Med. 2015;16(1):48–56.
   PubMed Web of Science ®Google Scholar
• Piconi S, Parisotto S, Rizzardini G, et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood. 2011;118(12):3263–3272.
   PubMed Web of Science ®Google Scholar
• Paton NI, Goodall RL, Dunn DT, et al. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. JAMA. 2012;308(4):353–361.
   PubMed Web of Science ®Google Scholar
• Jiang MC, Lin JK, Chen SS. Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine. Biochem Biophys Res Commun. 1996;226(1):1–7.
   PubMed Web of Science ®Google Scholar
• Rayne F, Vendeville A, Bonhoure A, et al. The ability of chloroquine to prevent tat-induced cytokine secretion by monocytes is implicated in its in vivo anti-human immunodeficiency virus type 1 activity. J Virol. 2004;78(21):12054–12057.
   PubMed Web of Science ®Google Scholar
• Naarding MA, Baan E, Pollakis G, et al. Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes. Retrovirology. 2007;4(1):6.
   PubMedGoogle Scholar
• van Loosdregt J, Spreafico R, Rossetti M, et al. Hydroxychloroquine preferentially induces apoptosis of CD45RO+ effector T cells by inhibiting autophagy: a possible mechanism for therapeutic modulation of T cells. J Allergy Clin Immunol. 2013;131(5):1443–6.e1.
   PubMed Web of Science ®Google Scholar
• Brouwers J, Vermeire K, Schols D, et al. Development and in vitro evaluation of chloroquine gels as microbicides against HIV-1 infection. Virology. 2008;378(2):306–310.
   PubMed Web of Science ®Google Scholar
• Chen Y, Traore YL, Yang S, et al. Implant delivering hydroxychloroquine attenuates vaginal T lymphocyte activation and inflammation. J Control Release. 2018May;277:102–113.
   PubMed Web of Science ®Google Scholar
• Traore YL, Chen Y, Bernier AM, et al. Impact of hydroxychloroquine-loaded polyurethane intravaginal rings on Lactobacilli. Antimicrob Agents Chemother. 2015;59(12):7680–7686.
   PubMed Web of Science ®Google Scholar
• Murray SM, Down CM, Boulware DR, et al. Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol. 2010;84(22):12082–12086.
   PubMed Web of Science ®Google Scholar
• Paton NI, Aboulhab J. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks. HIV Med. 2005;6(1):13–20.
   PubMed Web of Science ®Google Scholar
• Sperber K, Chiang G, Chen H, et al. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clin Ther. 1997;19(5):913–923.
   PubMed Web of Science ®Google Scholar
• Sperber K, Louie M, Kraus T, et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther. 1995;17(4):622–636.
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Bourguignon P, Willekens J, et al. Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine. Clin Vaccine Immunol. 2014;21(3):302–311.
   PubMedGoogle Scholar
• Neely M, Kalyesubula I, Bagenda D, et al. Effect of chloroquine on human immunodeficiency virus (HIV) vertical transmission. Afr Health Sci. 2003;3(2):61–67.
   PubMedGoogle Scholar
• Pardridge WM, Yang J, Diagne A. Chloroquine inhibits HIV-1 replication in human peripheral blood lymphocytes. Immunol Lett. 1998;64(1):45–47.
   PubMed Web of Science ®Google Scholar
• Savarino A, Gennero L, Chen HC, et al. Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity. AIDS. 2001;15(17):2221–2229.
   PubMed Web of Science ®Google Scholar
• Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev. 2009;22(4):564–581.
   PubMed Web of Science ®Google Scholar
• Borges MC, Castro LA, Fonseca BA. Chloroquine use improves dengue-related symptoms. Mem Inst Oswaldo Cruz. 2013;108(5):596–599.
   PubMed Web of Science ®Google Scholar
• Tsai YT, Chang SY, Lee CN, et al. Human TLR3 recognizes dengue virus and modulates viral replication in vitro. Cell Microbiol. 2009;11(4):604–615.
   PubMed Web of Science ®Google Scholar
• Randolph VB, Winkler G, Stollar V. Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Virology. 1990;174(2):450–458.
   PubMed Web of Science ®Google Scholar
• Gandini M, Gras C, Azeredo EL, et al. Dengue virus activates membrane TRAIL relocalization and IFN-α production by human plasmacytoid dendritic cells in vitro and in vivo. PLoS Negl Trop Dis. 2013 6;7(6):e2257.
   PubMed Web of Science ®Google Scholar
• Tricou V, Minh NN, Van TP, et al. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis. 2010;4(8):e785.
   PubMed Web of Science ®Google Scholar
• Farias KJ, Machado PR, Muniz JA, et al. Antiviral activity of chloroquine against dengue virus type 2 replication in Aotus monkeys. Viral Immunol. 2015;28(3):161–169.
   PubMed Web of Science ®Google Scholar
• Farias KJ, Machado PR, da Fonseca BA. Chloroquine inhibits dengue virus type 2 replication in Vero cells but not in C6/36 cells. ScientificWorldJournal. 2013;2013:282734.
   PubMedGoogle Scholar
• Farias KJ, Machado PR, de Almeida Junior RF, et al. Chloroquine interferes with dengue-2 virus replication in U937 cells. Microbiol Immunol. 2014;58(6):318–326.
   PubMed Web of Science ®Google Scholar
• Han Y, Pham HT, Xu H, et al. Antimalarial drugs and their metabolites are potent Zika virus inhibitors. J Med Virol. 2019;91(7):1182–1190.
   PubMed Web of Science ®Google Scholar
• Li C, Zhu X, Ji X, et al. Chloroquine, a FDA-approved drug, prevents Zika virus infection and its associated congenital microcephaly in mice. EBioMedicine. 2017;24:189–194.
   PubMed Web of Science ®Google Scholar
• Delvecchio R, Higa LM, Pezzuto P, et al. Chloroquine, an endocytosis blocking agent, inhibits Zika virus infection in different cell models. Viruses. 2016;8(12). DOI:10.3390/v8120322
   PubMed Web of Science ®Google Scholar
• Cao B, Parnell LA, Diamond MS, et al. Inhibition of autophagy limits vertical transmission of Zika virus in pregnant mice. J Exp Med. 2017;214(8):2303–2313.
   PubMed Web of Science ®Google Scholar
• Shiryaev SA, Mesci P, Pinto A, et al. Repurposing of the anti-malaria drug chloroquine for Zika virus treatment and prophylaxis. Sci Rep. 2017;7(1):15771.
   PubMedGoogle Scholar
• Plantone D, Koudrivtseva T. Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Invest. 2018;38(8):653–671.
   PubMed Web of Science ®Google Scholar
• Brighton SW. Chloroquine phosphate treatment of chronic chikungunya arthritis. S Afr Med J. 1984;66(6):217–218.
   PubMed Web of Science ®Google Scholar
• De Lamballerie X, Boisson V, Reynier JC, et al. On chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis. 2008;8(6):837–839.
   PubMed Web of Science ®Google Scholar
• Roques P, Thiberville SD, Dupuis-Maguiraga L, et al. Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection. Viruses. 2018;10(5):5.
   Web of Science ®Google Scholar
• Renapurkar DK. Efficacy of chloroquine in management of chikungunya: a phase IV clinical trial. Int J Pharma Bio Sci. 2011;2(1):407–412.
   Google Scholar
• Ahmed M, Shantharam N, Visweswara Reddy YJ. Randomized clinical trial in chikungunya arthritis cases. J Evol Med Dent Sci. 2012;1(5):841–847.
   Google Scholar
• Chopra A, Saluja M, Venugopalan A. Effectiveness of chloroquine and inflammatory cytokine response in patients with early persistent musculoskeletal pain and arthritis following chikungunya virus infection. Arthritis Rheumatol. 2014;66(2):319–326.
   PubMed Web of Science ®Google Scholar
• Ravindran V, Alias G. Efficacy of combination DMARD therapy vs. hydroxychloroquine monotherapy in chronic persistent chikungunya arthritis: a 24-week randomized controlled open label study. Clin Rheumatol. 2017;36(6):1335–1340.
   PubMed Web of Science ®Google Scholar
• Khan M, Santhosh SR, Tiwari M, et al. Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against chikungunya virus in vero cells. J Med Virol. 2010;82(5):817–824.
   PubMed Web of Science ®Google Scholar
• Peymani P, Ghavami S, Yeganeh B, et al. Effect of chloroquine on some clinical and biochemical parameters in non-response chronic hepatitis C virus infection patients: pilot clinical trial. Acta Biomed. 2016;87(1):46–53.
   PubMedGoogle Scholar
• Kouroumalis EA, Koskinas J. Treatment of chronic active hepatitis B (CAH B) with chloroquine: a preliminary report. Ann Acad Med Singapore. 1986;15(2):149–152.
   PubMedGoogle Scholar
• Helal GK, Gad MA, Abd-Ellah MF, et al. Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients. J Med Virol. 2016;88(12):2170–2178.
   PubMed Web of Science ®Google Scholar
• Accapezzato D, Visco V, Francavilla V, et al. Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo. J Exp Med. 2005;202(6):817–828.
   PubMed Web of Science ®Google Scholar
• Mizui T, Yamashina S, Tanida I, et al. Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy. J Gastroenterol. 2010;45(2):195–203.
   PubMed Web of Science ®Google Scholar
• Chandramohan M, Vivekananthan SC, Sivakumar D, et al. Preliminary report of anti-hepatitis C virus activity of chloroquine and hydroxychloroquine in huh-5-2 cell line. Indian J Pharm Sci. 2006;68(4):538–540.
   Google Scholar
• Akpovwa H. Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity. Cell Biochem Funct. 2016;34(4):191–196.
   PubMed Web of Science ®Google Scholar
• Du X, Zuo X, Meng F, et al. Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities. Biochem Biophys Res Commun. 2020;522(4):862–868.
   PubMed Web of Science ®Google Scholar
• Dowall SD, Bosworth A, Watson R, et al. Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. J Gen Virol. 2015;96(12):3484–3492.
   PubMed Web of Science ®Google Scholar
• Long J, Wright E, Molesti E, et al. Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. Version 2. F1000Res. 2015;4(30). DOI:10.12688/f1000research.6085.2
   PubMedGoogle Scholar
• Falzarano D, Safronetz D, Prescott J, et al. Lack of protection against ebola virus from chloroquine in mice and hamsters. Emerg Infect Dis. 2015;21(6):1065–1067.
   PubMed Web of Science ®Google Scholar
• Madrid PB, Panchal RG, Warren TK, et al. Evaluation of ebola virus inhibitors for drug repurposing. ACS Infect Dis. 2015 Jul 10;1(7):317–326.
   PubMed Web of Science ®Google Scholar
• Kouznetsova J, Sun W, Martínez-Romero C, et al. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg Microbes Infect. 2014;3(12):e84.
   PubMed Web of Science ®Google Scholar
• Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2(1):69.
   PubMed Web of Science ®Google Scholar
• Keyaerts E, Vijgen L, Maes P, et al. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004;323(1):264–268.
   PubMed Web of Science ®Google Scholar
• Kono M, Tatsumi K, Imai AM, et al. Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK. Antiviral Res. 2008;77(2):150–152.
   PubMed Web of Science ®Google Scholar
• Barnard DL, Day CW, Bailey K, et al. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir Chem Chemother. 2006;17(5):275–284.
   PubMedGoogle Scholar
• Dyall J, Coleman CM, Hart BJ, et al. Repurposing of clinically developed drugs for treatment of middle east respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014;58(8):4885–4893.
   PubMed Web of Science ®Google Scholar
• de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-Approved compound library identifies four small-molecule inhibitors of middle east respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58(8):4875–4884.
   PubMed Web of Science ®Google Scholar
• Cong Y, Hart BJ, Gross R, et al. MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells. PLoS One. 2018 22;13(3):e0194868.
   PubMed Web of Science ®Google Scholar
• Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020. DOI:10.1093/cid/ciaa237
   Web of Science ®Google Scholar
• Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;20:105949.
   Google Scholar
• WHO Director-General’s opening remarks at the media briefing on COVID-19-11. 2020 Mar [cited 2020 Apr 10]. Available from: [https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-atthe- media-briefing-on-covid-19—11-march-2020]
   Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271.
   PubMed Web of Science ®Google Scholar
• Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6(1):16.
   PubMed Web of Science ®Google Scholar
• Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents. 2020;55(3):105923.
   PubMed Web of Science ®Google Scholar
• Fantini J, Scala CD, Chahinian H, et al. Structural and molecular modelling studies reveal a new mech- anism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents. 2020 Apr;3(5):105960.
   Google Scholar
• Derendorf H. Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin. Int J Antimicrob Agents. 2020;7(6):106007.
   Google Scholar
• Roldan EQ, Biasiotto G, Magro P, et al. The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): a role for iron homeostasis? Pharmacol Res. 2020;158:104904.
   PubMed Web of Science ®Google Scholar
• Wolfram J, Nizzero S, Liu H, et al. A chloroquine-induced macrophage-preconditioning strategy for improved nanodelivery. Sci Rep. 2017;7(1):13738.
   PubMed Web of Science ®Google Scholar
• Devaux CA, Rolain JM, Coson P, et al. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19. Int J Antimicrob Agents. 2020;12(5):105938.
   Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.
   PubMed Web of Science ®Google Scholar
• Müller C, Hardt M, Schwudke D, et al. Inhibition of cytosolic phospholipase a(2)α impairs an early step of coronavirus replication in cell culture. J Virol. 2018;92(4):e01463–17.
   PubMed Web of Science ®Google Scholar
• Ha DR, Kuo J, Aung PS, et al. Outpatient hydroxychloroquine prescribing at a large academic health system during the COVID-19 pandemic. Infect Control Hosp Epidemiol. 2020;1–2. DOI:10.1017/ice.2020.243
   PubMed Web of Science ®Google Scholar
• Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849.
   PubMed Web of Science ®Google Scholar
• Mahevas M, Tran VT, Roumier M, et al. Clinical efficacy of hydroxychloroquine in patients with COVID-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020;369:m1844.
   PubMed Web of Science ®Google Scholar
• Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in NewYork State. JAMA. 2020;e208630. DOI:10.1001/jama.2020.8630
   Web of Science ®Google Scholar
• Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;NEJMoa2012410. DOI:10.1056/NEJMoa2012410
   Web of Science ®Google Scholar
• Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs lowdoses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection a randomized clinical trial. JAMA Network Open. 2020 24;3(4):e208857.
   PubMed Web of Science ®Google Scholar
• Indian Council of Medical Research [Internet]. Advisory on the use of hydroxychloroquin as prophylaxis for SARSCoV2 infection. [cited 2020 Mar 24]. Available from: https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxy chloroquinasprophylaxisforSARSCoV2infection.pdf
   Google Scholar
• Chorin E, Wadhwani L, Magnani S, et al. Torsade De Pointes in Patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm. 2020;S1547-5271(20):30435–5.
   Google Scholar
• Writing Group of the Johns Hopkins University and Johns Hopkins Hospital COVID-19 Treatment Guidance Working Group [Internet]. JHMI clinical guidance for available pharmacologic therapies for COVID-19. [cited 2020 Apr 10]. Available from: https://www.hopkinsguides.com/hopkins/ub?cmd=repview&t ype=479-1112&name=3_538747_PDF
   Google Scholar
• Agrawal S, Goel AD, Gupta N. Emerging prophylaxis strategies against COVID-19. Monaldi Arch Chest Dis. 2020;90(1). DOI:10.4081/monaldi.2020.1289
   Web of Science ®Google Scholar
• Shah S, Das S, Jain A, et al. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). Int J Rheum Dis. 2020;23(5):613–619.
   PubMed Web of Science ®Google Scholar
• Gendelman O, Amital H, Bragazzi NL, et al. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: insights from a large healthcare database analysis. Autiommun Rev. 2020;19(7):102566.
   PubMed Web of Science ®Google Scholar
• Perinel S, Launay M, Botelho-Nevers É, et al. Towards optimization of hydroxychloroquine dosing in intensive care unit COVID-19 patients. Clin Infect Dis. 2020. DOI:10.1093/cid/ciaa394
   PubMed Web of Science ®Google Scholar
• Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci). 2020;49(1). DOI:10.3785/j.issn.1008-9292.2020.03.03
   Google Scholar
• Million M, Lagier JC, Gautret P, et al. Full-length title: early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis. 2020;101738. DOI:10.1016/j.tmaid.2020.101738
   PubMed Web of Science ®Google Scholar
• Huang M, Tang T, Pang P, et al. Treating COVID-19 with chloroquine. J Mol Cell Biol. 2020;12(4):322–325.
   PubMed Web of Science ®Google Scholar
• Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis. 2020;34:101663.
   PubMed Web of Science ®Google Scholar
• Martinson JA, Montoya CJ, Usuga X, et al. Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation. Antimicrob Agents Chemother. 2010;54(2):871–881.
   PubMed Web of Science ®Google Scholar